Abstract
The plasma form of the human enzyme platelet activating factor acetylhydrolase (PAF-AH) has been crystallized, and X-ray diffraction data were collected at a synchrotron source to a resolution of 1.47 Å. The crystals belong to space group C2, with unit cell parameters of a = 116.18, b = 83.06, c = 96.71 Å, and β = 115.09° and two molecules in the asymmetric unit. PAF-AH functions as a general anti-inflammatory scavenger by reducing the levels of the signaling molecule PAF. Additionally, the LDL bound enzyme has been linked to atherosclerosis due to its hydrolytic activities of pro-inflammatory agents, such as sn-2 oxidatively fragmented phospholipids.
Keywords: PAF-AH, lipoprotein associated phospholipase A2, Lp-PLA2, group VIIA PLA2, crystallization
Protein & Peptide Letters
Title: Crystallization and Preliminary X-Ray Crystallographic Analysis of Human Plasma Platelet Activating Factor Acetylhydrolase
Volume: 16 Issue: 1
Author(s): Uttamkumar Samanta, Cheryl Wilder and Brian J. Bahnson
Affiliation:
Keywords: PAF-AH, lipoprotein associated phospholipase A2, Lp-PLA2, group VIIA PLA2, crystallization
Abstract: The plasma form of the human enzyme platelet activating factor acetylhydrolase (PAF-AH) has been crystallized, and X-ray diffraction data were collected at a synchrotron source to a resolution of 1.47 Å. The crystals belong to space group C2, with unit cell parameters of a = 116.18, b = 83.06, c = 96.71 Å, and β = 115.09° and two molecules in the asymmetric unit. PAF-AH functions as a general anti-inflammatory scavenger by reducing the levels of the signaling molecule PAF. Additionally, the LDL bound enzyme has been linked to atherosclerosis due to its hydrolytic activities of pro-inflammatory agents, such as sn-2 oxidatively fragmented phospholipids.
Export Options
About this article
Cite this article as:
Samanta Uttamkumar, Wilder Cheryl and Bahnson J. Brian, Crystallization and Preliminary X-Ray Crystallographic Analysis of Human Plasma Platelet Activating Factor Acetylhydrolase, Protein & Peptide Letters 2009; 16 (1) . https://dx.doi.org/10.2174/092986609787049321
DOI https://dx.doi.org/10.2174/092986609787049321 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microglia Activation Precedes the Anti-Opioid BDNF and NMDA Receptor Mechanisms Underlying Morphine Analgesic Tolerance
Current Pharmaceutical Design Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Hepatic Diseases Related to Triglyceride Metabolism
Mini-Reviews in Medicinal Chemistry Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Current Concepts in the Understanding of Pain in the Rheumatic Diseases
Current Rheumatology Reviews Subject Index to Volume 4
Mini-Reviews in Medicinal Chemistry All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Dasatinib in the Treatment of Chronic Myeloid Leukemia
Current Signal Transduction Therapy Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Ablation of TRPV1 Elevates Nocturnal Blood Pressure in Western Diet-fed Mice
Current Hypertension Reviews Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Proteins in Complement, Immune, and Clotting Cascades and their Role in Preterm Births
Current Protein & Peptide Science Xenobiotic Metabolism in Human Skin and 3D Human Skin Reconstructs: A Review
Current Drug Metabolism